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A B S T R A C T

Background: The most common B-cell cancers, chronic lymphocytic leukemia/lymphoma (CLL), follicular and
diffuse large B-cell (FL, DLBCL) lymphomas, have distinct clinical courses, yet overlapping “cell-of-origin”.
Dynamic changes to the epigenome are essential regulators of B-cell differentiation. Therefore, we reasoned
that these distinct cancers may be driven by shared mechanisms of disruption in transcriptional circuitry.
Methods: We compared puriﬁed malignant B-cells from 52 patients with normal B-cell subsets (germinal
center centrocytes and centroblasts, naïve and memory B-cells) from 36 donor tonsils using >325 high-resolution molecular proﬁling assays for histone modiﬁcations, open chromatin (ChIP-, FAIRE-seq), transcriptome
(RNA-seq), transcription factor (TF) binding, and genome copy number (microarrays).
Findings: From the resulting data, we identiﬁed gains in active chromatin in enhancers/super-enhancers that
likely promote unchecked B-cell receptor signaling, including one we validated near the immunoglobulin
superfamily receptors FCMR and PIGR. More striking and pervasive was the profound loss of key B-cell identity TFs, tumor suppressors and their super-enhancers, including EBF1, OCT2(POU2F2), and RUNX3. Using a
novel approach to identify transcriptional feedback, we showed that these core transcriptional circuitries are
self-regulating. Their selective gain and loss form a complex, iterative, and interactive process that likely
curbs B-cell maturation and spurs proliferation.
Interpretation: Our study is the ﬁrst to map the transcriptional circuitry of the most common blood cancers.
We demonstrate that a critical subset of B-cell TFs and their cognate enhancers form self-regulatory transcriptional feedback loops whose disruption is a shared mechanism underlying these diverse subtypes of Bcell lymphoma.
Funding: National Institute of Health, Siteman Cancer Center, Barnes-Jewish Hospital Foundation, Doris Duke
Foundation.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction
Development of B lymphocytes from lymphoid progenitors is less
a linear progression than a web of decision points in which response
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to internal and external cues drives phenotypic change and the next
differentiation stage. Signiﬁcant perturbations at developmental
decision points should result in cell death, but rarely, cells escape this
quality control system. Dynamic changes to the epigenome are essential regulators of B-cell differentiation, as demonstrated by the consistent alterations observed at B-cell speciﬁc promoters and
enhancers during B-cell maturation [1,2] and the detrimental effects
of epigenetic modiﬁer knockouts [3 6]. Several of these modiﬁers
are also connected to the pathogenesis of human and murine B-cell
cancers [7 9]. Widespread changes to DNA methylation landscapes
have been reported in all major B-cell cancers, though unlike other
blood cancers, mutations in DNA methylation genes are rare
[10 15].
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Research in context
Evidence before this study
Chronic lymphocytic leukemia/lymphoma (CLL), follicular and diffuse large B-cell lymphomas (FL, DLBCL), are distinct in their presentation and clinical course, yet overlap in their “cell-of-origin”
or normal counterpart B-cells. Previous studies showed that
dynamic changes to the epigenome are essential regulators of
normal B-cell differentiation. Notably, no studies have compared
epigenetic and transcriptional regulation in these three lymphomas, which comprise the majority of blood cancers in the U.S.
Added value of this study
We reasoned that these distinct cancers may be driven by
shared mechanisms of dysregulation of transcriptional circuitry, a question that has not been previously addressed to our
knowledge. Our study is the ﬁrst to map the transcriptional circuitry of the most common blood cancers. We report the results
of our integrative analysis comparing epigenome, transcriptome, and genome copy number data from puriﬁed malignant
B cells from 52 patients with sorted normal B-cell subsets from
36 donor tonsils, comprising 328 high resolution molecular
proﬁling studies. Our studies identiﬁed selective gain and loss
of self-regulating transcriptional regulators, including B-cell
receptor signaling and identity factors, as well as tumor suppressors, that together form an iterative feed-forward process
that curbs B-cell maturation and spurs proliferation.
Implications of all the available evidence
Our results suggest that diverse subtypes of B-cell cancer arise
due to disruption of shared transcriptional circuitry involving
core B-cell TFs and their cognate enhancers. We believe that
our ﬁndings are novel and impactful in that they demonstrate a
mechanism for perpetuating transcriptional and epigenetic
dysregulation that is shared across diverse human B-cell cancers. These shared B-cell factors and their regulatory circuits
represent previously unrecognized targets for future study and
potential therapies for the most common blood cancers.

The essential nature of histone modiﬁcations for epigenetic regulation of gene expression in B cells has been known for more than
50 years [16]. More recently, chromatin immunoprecipitation
sequencing (ChIP-seq) studies across B-cell developmental stages
have elucidated coordinated changes in histone acetylation and
methylation linked to modulation of gene expression [1,2]. Effective
B-cell maturation in the germinal center relies upon temporally regulating the activation or repression of proliferation and differentiation
pathways, often via bivalent chromatin states marking key promoters
[8,17]. Not surprisingly, mutation of essential chromatin modiﬁers
and consequent alterations to histone landscapes is a hallmark of germinal center B-cell cancers, particularly follicular lymphoma (FL) and

diffuse large B-cell lymphoma (DLBCL) [8,18 20]. Another mature Bcell cancer, chronic lymphocytic leukemia (CLL), harbors mutations
in a different set of epigenetic modiﬁer genes, albeit at much lower
frequency [12,21]. Nevertheless, there are widespread changes to the
chromatin landscape in CLL [22,23]. Notably, the chromatin landscapes of germinal center B-cell lymphomas (FL, DLBCL) and CLL have
not been compared to identify unique and shared alterations that
may illuminate pathways that are subtype-speciﬁc and shared,
respectively, to the pathogenesis of each cancer type.
The process of B-cell differentiation generates a number of cellular
states with distinct transcriptional and surface marker proﬁles, and
importantly, different vulnerabilities for transformation to B-cell lymphoma/leukemia. Thus, identiﬁcation of BCL-speciﬁc pathways requires
comparison to the most similar normal B-cell subset, sometimes
referred to as cell-of-origin [24 26]. Comparisons of whole transcriptomes, cell surface markers, and epigenome landscapes have demonstrated a close similarity between FL and centrocytes from the GC light
zone [18,27]. The GCB subtype of DLBCL also resembles GC centrocytes,
while the activated B-cell (ABC) subtype exhibits a proﬁle more similar
to centroblasts from the GC dark zone [27] or, more recently, has been
compared to memory B cells [28]. The cell of origin for CLL is likewise
dependent upon subtype, with unmutated IGHV CLL compared to pregerminal center naïve B cells and mutated IGHV CLL compared to postgerminal center memory B cell [10,29,30]. Given the overlap in cell of
origin, these distinct B cell cancers may be driven by dysregulation of
shared epigenetic mechanisms.
Epigenetic modiﬁcations contribute to transcriptional regulation via
a range of mechanisms, from structural genome organization to recruitment of transcriptional regulatory factors [31]. The genome is spatially
organized into compartments deﬁned by a shared chromatin state and
organized into chromatin loops between enhancers and promoters of
co-expressed genes within the domain. The domain boundaries and
chromatin loops are anchored by CTCF and cohesin proteins [32 36].
Super enhancers (SEs) are clusters of highly active regulatory elements
marked by high levels of active chromatin marks (e.g., H3K27ac), transcriptional regulatory proteins (e.g., Mediator), and master transcription
factors (TFs) that regulate high expression of key cell identity genes
[37 39]. These identity-driving factors, sometimes referred to as “core
TFs”, form interconnected transcriptional loops that establish and maintain cell-type speciﬁc expression programs and disruption of this core
transcriptional regulatory circuitry is likely oncogenic [40]. Given these
characteristics, it is not surprising that SEs are also enriched in CTCF and
cohesin binding to closely associate their transcriptional power with target genes for cell identity, while isolating them from other genes
[41 43]. In many cancers, including BCL, altered genome copy number
and/or epigenetic states create de novo SEs or increase the activity of
existing SEs that then act to promote oncogenesis [44 48]. However, it
is not known whether FL, DLBCL, and CLL harbor shared or disease-speciﬁc SE proﬁles and how each group contributes to pathogenesis.
To address these outstanding questions, we compared FL, DLBCL,
and CLL and normal B lymphocytes to identify shared and distinct
epigenetic perturbations that promote oncogenesis. We puriﬁed
malignant B cells from lymph node and peripheral blood from 52
patients (18 FL, 11 DLBCL, 23 CLL) and isolated normal B-cell subsets

Table 1
Shows the patient characteristics (age, sex, diagnosis) for B-cell cancer patients in the WUSM study.
Disease

Number

M/F

Age, years (Median/Range)

Chronic Lymphocytic Leukemia/Lymphoma (CLL)
Diffuse Large B Cell Lymphoma (DLBCL)
Activated B Cell (ABC) type
Germinal Center B cell (GCB) type
Follicular Lymphoma (FL)
Stage 1-2
Stage >2

23
11
6
5
18
15
3

12/11
6/5

62 (38 - 86)
66 (50 - 77)

7/11

53 (35 - 78)
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Fig. 1. Study design, biospecimens, B-cell puriﬁcation, molecular proﬁling, experiments and data analysis workﬂow. A) Lymph node biopsies and peripheral blood were collected
from BCL patients (18 FL, 11 DLBCL, 23 CLL) and tonsils [36] from healthy donors. We puriﬁed CD19+ malignant B cells from lymph node biopsies (FL, CLL, DLBCL) or peripheral blood
(CLL), and isolated CD19+ normal B-cells from tonsils [20]. From additional tonsils we sorted germinal center (GC) centrocytes (CD19+CD10+CD44loCXCR4 , 5), GC centroblasts
(CD19+CD10+CD44loCXCR4+, 5), naive (CD19+CD5 CD27 , 3), and memory (CD19+CD5 CD27+, 3) control B-cell subsets. From these samples, we performed chromatin immunoprecipitation sequencing (ChIPseq, H3K27ac 51, H3ac 47, H3K4me1 35)), open chromatin proﬁling (FAIREseq - 45), RNA sequencing (RNAseq - 28) and microarrays [80], and
whole genome copy number studies (SNP microarray - 42), totaling 328 high resolution molecular proﬁling studies. Our Integrative Analysis pipeline compared BCL subtypes to
healthy control B-cells and identiﬁed copy number alterations, differentially bound enhancers, differentially expressed genes, and enhancer-gene associations. These studies also
identiﬁed >1300 super-enhancers, many of which correlate with signiﬁcantly altered expression of neighboring genes in BCL compared to control B-cells. We validated one of these,
a novel super-enhancer with high levels of epigenetic activity and expression of two nearby genes, FCMR and PIGR, across BCL subtypes, using luciferase reporter assays and demonstrate high levels of FCMR and PIGR protein in primary BCL cells using ﬂow cytometry and immunoﬂuorescence (IF) staining. B) Heatmap shows assays performed for each sample:
healthy control (HC) CD19+ B cells; NAIVE B cells; Memory B cells (MEM); Centroblast (CB); Centrocyte (CC); CLL; DLBCL; FL.
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(GC centrocytes and centroblasts, naïve and memory B cells) from 36
donor tonsils and subjected them to chromatin immunoprecipitation
(ChIP) and sequencing for H3K4me1, H3K9/14ac, and H3K27ac, FAIREseq for open chromatin; gene expression and genome copy number
were also proﬁled. These epigenetic studies identiﬁed novel SEs that
likely promote aberrant BCR signaling and a striking loss of key B-cell
transcription factors (TF) and tumor suppressors across BCL subtypes
that we connected to the disruption of their linked SEs. Together, these
results suggest that a critical subset of B-cell TFs and their cognate SEs
form self-regulatory transcriptional feedback loops whose disruption is
a shared mechanism driving mature B-cell leukemia/lymphoma.

used to derive consensus peak sets for each histone mark and accessible
chromatin, requiring peaks to overlap in at least three samples for each
ChIP-seq or FAIRE-seq assay in order to be merged and retained. The
consensus peaksets for each assay were then concatenated and merged
to derive a list of putative regulatory elements. DiffBind was then used
to determine differentially bound/accessible regions between sample
groups for each assay. ChIPseeker [15] (v1.22.0) was used to annotate
peaks with hg19 UCSC knownGene annotations. Averaged signal heatmaps were generated by merging all bam ﬁles for a group with samtools
and subsequent visualization of RPKM-normalized reads in EaSeq [16]
(v1.111). All bed ﬁle manipulations were performed with bedtools2
[17] (v2.29.2).

2. Methods
2.4. RNA-seq and expression microarrays
2.1. Ethics
De-identiﬁed peripheral blood and lymph node biopsies were
obtained from FL, DLBCL, and CLL patients, and excised tonsils
obtained from otherwise healthy tonsillectomy patients (Table 1 and
Fig. 1B) seen at Washington University School of Medicine who provided informed consent under IRB-approved protocols (IRB ID #:
201607102 and 201108251) in concordance with the Declaration of
Helsinki.
2.2. Human specimen processing
CD19+ B cells were puriﬁed from peripheral blood, lymph node or
tonsil as in [18]. B-cell subsets isolated: centroblast CD10+CD44loCXCR4+
and centrocyte CD10+CD44loCXCR4 [18], naive CD27 CD5 and memory CD27+CD5 [49] populations. Speciﬁcally, CD19+ B cells were puriﬁed from lymph node by mechanical dissociation and ﬂushing of the
tissue with sort buffer (PBS, 1% FBS, 2 mM EDTA), followed by two
rounds of red blood cell lysis (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM
EDTA) for 10 minutes each. Peripheral blood was subjected to at least
four rounds of red blood cell lysis. CD19+ B cells were then puriﬁed
from PBMCs via an EasySep CD19+ Positive Selection Kit (StemCell Technologies cat. 17854) or using CD19 MicroBeads (Miltenyi Biotec cat.
130-050-301) per the manufacturer’s instructions to >90% purity as
assessed by ﬂow cytometry (CD19-APC, Miltenyi Biotec cat. 130-110351). Tonsillar tissues were mechanically disrupted and subjected to
red blood cell lysis. B cell subsets were isolated by CD19 MicroBeads
and ﬂuorescence activated cell sorting to collect CD10+CD44loCXCR4+
(Centroblast), CD10+CD44loCXCR4 (Centrocyte), CD27-CD5- (Naive),
and CD27+CD5- (Memory) populations. Due to yield constraints, some
samples were not subjected to all assays.
2.3. ChIP-seq
Crosslinking of 3-5 £ 106 cells and chromatin immunoprecipitation
for H3K9/K14ac (EMD-Millipore 06-599), H3K27ac (Abcam ab4729),
and H3K4me1 (Abcam ab8895) was performed as described [7]. DNA
was sequenced by the Washington University Genome Technology
Access Center on an Illumina Hi-Seq 2000/2500/3000 to generate 42 or
50 bp single-end reads. Reads were aligned to hg19 with bowtie2 [8]
(v2.2.5) using default settings. Reads in ENCODE blacklisted regions [9]
were removed with samtools [10] (v1.9). Peaks were called with
MACS25 (v2.1.0.20150420) with the parameters
nomodel
shiftsize=150 and input controls. RPKM normalized genome browser
tracks were created with deepTools’(11) (v3.3.0) bamCoverage utility
with settings binSize 10 extendReads 150 normalizeUsing RPKM
and visualized on the UCSC genome browser. ChIPQC [12] (v1.21.0) was
used for quality control, and samples with fewer than 8.5% (H3ac), 4.5%
(H3K27ac), 2.5% (FAIRE), or 7.5% (H3K4me1) reads in peaks were
removed from subsequent analyses. ROSE [13] was used to call super
enhancers for each sample with default settings and input controls, and
a consensus set was derived using DiffBind [14] (v2.14.0). DiffBind was

RNA was isolated from 1-2 £ 106 cells from each sample with a Qiagen RNeasy kit (Qiagen cat. 74104). rRNA-depleted (Ribo-Zero, Epicentre, discontinued) libraries were prepared using TruSeq RNA Sample
kits with indexed adaptors (Illumina) and subjected to 2 £ 100 bp
paired-end sequencing on an Illumina Hi-Seq 2000 by the Washington
University Genome Technology Access Center. Reads were aligned to
hg19 with Gencode v31 annotations using STAR [18] (v2.5.3a). RPKM
normalized tracks were created with deepTools'(11) (v3.3.0) bamCoverage utility and visualized on the UCSC genome browser. Read quantiﬁcation was performed by Salmon [19] (v0.14.1) using Gencode v31
annotations after generating a decoy-aware transcriptome index, and
differential gene expression analyses performed with the DESeq2 [20] R
package (v1.26.0). The pheatmap R package was used for heatmap generation and associated clustering. Manual gene curation was performed
with Genotify (v1.2.2) [21]. For expression microarrays, RNA was puriﬁed, ampliﬁed, labeled and hybridized as in [18] on Affymetrix Human
Gene 2.0ST arrays (cat. 902112) according to manufacturer instructions.
Data was analyzed with Applied Biosystems Transcriptome Analysis
Console (v4.0.2.15) using RMA normalization, HuGene2.0.na36 annotations, and default settings. Differential expression analysis was performed through the Transcriptome Analysis Console with limma [50].
Clonotyping was performed on raw RNA-seq reads with MiXCR
(v3.0.12) [51] with the parameters -starting-material rna -only-productive -receptor-type bcr. The clonotypes were converted to VDJtools format with VDJtools (v1.2.1) [52] Convert functionality with the -S mixcr
parameter. Gene usage was calculated with the CalcSegmentUsage utility and TCR segments were removed prior to visualization.
2.5. DNA SNP/copy number microarrays
Genomic DNA from 1 £ 106 lymphoma or healthy control B cells
isolated as above was puriﬁed via a Qiagen DNeasy Blood and Tissue
kit (cat. 69504) and hybridized (0.5 ug) to Affymetrix Genome-Wide
Human SNP6.0 Array GeneChip microarrays (ThermoFisher Scientiﬁc
cat. 901150) according to the manufacturer’s instructions. Arrays
were processed using the Affymetrix Genotyping Console (v4.2) with
hg19 na36 annotations. Samples were genotyped and copy number
signal derived with regional GC correction and signal smoothing
using default parameters and the HapMap reference. Resulting log2
ratios at each marker for each BCL array were concatenated and used
as input for circular binary segmentation (CBS) [53] via the DNAcopy
(v1.58.0) R package with min.width = 5. Additional visualizations
were created with CNVkit (v0.9.3) [54] and the copynumber R package (v1.26.0) [55].
2.6. Pathway enrichment analyses
Gene pathway enrichment analyses were performed on the g:Proﬁler webserver [56] (version e98_eg45_p14_ce5b097), limiting terms
to those with 5 and <1000 members and g:SCS multiple testing correction threshold of 0.05. For motif enrichment, term size limits were
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removed, and the lowest p-value was retained if there were multiple
motifs for a given gene.
2.7. Luciferase assays
Putative regulatory elements were PCR-ampliﬁed from genomic
DNA isolated from Raji (ATCC CCL-86; RRID:CVCL_0511) or LS180 cells
(ATCC CCL-187; RRID:CVCL_0397) via phenol chloroform precipitation.
Primer sequences are available in Table S6. PCR products were gelextracted (Qiagen cat. 28706), digested with BamHI (New England BioLabs cat. R3136) and SalI (New England BioLabs cat. R3138), and ligated
downstream of luciferase in the pGL3 Promoter Luciferase Reporter vector (Promega cat. E1761) overnight at 23 °C with T4 DNA ligase (New
England BioLabs, cat. M0202S). Sanger sequencing conﬁrmed successful
cloning. 100 ng of each reporter plasmid and 15 ng of pRL renilla luciferase vector (Promega cat. E2231) were transfected into 20k LS180 cells in
each well of a 96 well plate in triplicate with Lipofectamine 2000 (ThermoFisher Scientiﬁc cat. 11668019) per the manufacturer’s instructions
with 100 mL of MEM (ThermoFisher Scientiﬁc cat. 11095-080) supplemented with 1% penicillin/streptomycin and 10% fetal bovine serum.
2.5 mg of each reporter plasmid and 50 ng of pRL renilla luciferase vector were nucleofected into 2 £ 10^6 Raji cells in 2 mL RPMI-1640 (ThermoFisher Scientiﬁc cat. 11875119) in each well of a 6 well plate with a
Nucleofector 2b (Lonza cat. AAB-1001) using the Human B Cell Nucleofector kit (Lonza cat. VAPA-1001) and the M-013 program per the manufacturer’s instructions. After 24 h incubation at 37 °C with 5% CO2,
LS180 media was replaced and luciferase activity read on a Cytation5
plate reader (BioTek cat. 12576) using the Dual-Glo Luciferase Assay
System (Promega cat. E2920) according to the manufacturer's instructions. Raji cells were spun down, resuspended in 200 mL of media, and
split into 3 wells of a 96 well plate prior to performing the assay. Assays
were read in triplicate and performed at least twice. The average ratios
between the ﬁreﬂy and renilla luciferase readings for each sample were
compared to the average ratio for the empty pGL3-promoter vector to
determine relative luciferase.
2.8. Immunoﬂuorescence and confocal microscopy
For immunoﬂuorescence and microscopy, 2 £ 105 CLL, MEC1
(DSMZ cat. ACC 497; RRID:CVCL_1870), or HH (ATCC cat. CRL-2015;
RRID:CVCL_1280) cells were placed on top of an 18 mm coverslip in
one well of a 12 well plate in PBS for 30 min at 37 °C to adhere. LS180
cells were seeded on top of the slip and allowed to attach to the coverslip in typical culture conditions overnight. Primary antibody for
PIGR (1:100, ThermoFisher Scientiﬁc cat. PA5-22096) was incubated
with cells for 2 hours at room temperature. Secondary antibody
(1:1000 goat anti-rabbit Alexa Fluor 594 ThermoFisher Scientiﬁc cat.
A-11037) was incubated with cells for 1 hour at room temperature in
the dark. Coverslips were mounted with ProLong Gold with DAPI
(ThermoFisher Scientiﬁc cat. P36941) overnight before sealing with
clear nail polish. Microscopy was performed on an Olympus ﬂuorescence microscope (BX-53) using an ApoN 60X/1.49 NA oil immersion
lens or a UPlanS-Apo 100X/1.4 oil immersion lens and cellSens
Dimension software. Identical exposure times (DAPI - 10 ms; PIGR 100 ms) were used for all cell types, and minor brightness adjustments were applied uniformly across images.
2.9. Flow cytometry
For ﬂow cytometry, 2 £ 105 freshly isolated PBMCs from peripheral
blood CLL samples were blocked with FcX Trustain (BioLegend cat.
422301) for 5 min in Sort Buffer (PBS, 2% FBS, 10 mM EDTA) before
incubation with 1 mg anti-FCMR antibody (Novus Biologicals cat.
H00009214-M01) or 1 mg mouse IgG2b isotype control (abcam cat.
ab170192) for 30 min at 25 °C. Cells were washed with sort buffer and
stained with goat anti-mouse IgG BrilliantViolet421 (BioLegend cat.

5

405317) and anti-CD19 APC (Miltenyi Biotec cat. 130-114-168) for
30 min. After washing, ﬂow cytometry was performed on a modiﬁed
Becton Dickinson FACScan ﬂow cytometer and analyzed using FlowJo
(v9.9.5) software. At least 3000 events were recorded for each sample.
2.10. Statistics
Unless otherwise indicated, statistical testing was performed with
GraphPad Prism (v8.3.0).
Role of the funding sources
The study sponsors had no role in the study design; collection,
analysis, and interpretation of data; in writing of the manuscript; or
in the decision to submit the paper for publication.
3. Results
3.1. Study overview and design
To generate a comprehensive map of the gene regulatory landscape
in normal and malignant mature B-cell lymphoma/leukemia (BCL), we
surveyed the active epigenomes and transcriptomes of primary biospecimens from FL, DLBCL, and CLL patients at the Washington University
School of Medicine and compared them to normal B-cell subsets puriﬁed
from donor tonsils (Fig. 1A). Clinical characteristics for BCL patients are
summarized in Table 1. Brieﬂy, we collected lymph node biopsies and
peripheral blood from BCL patients (18 FL, 11 DLBCL, 23 CLL) and 36 tonsils from healthy donors. We puriﬁed CD19+ malignant B cells from
lymph node biopsies (FL, CLL, DLBCL) or peripheral blood (CLL). We isolated CD19+ control B cells from tonsils and further sorted to obtain germinal center (GC) centrocytes (CD19+CD10+CD44loCXCR4 ) and GC
centroblasts (CD19+CD10+CD44loCXCR4+), naive (CD19+CD5 CD27 ),
and memory (CD19+CD5 CD27+) B-cell subsets [18,57]. Fig. 1B shows
each sample and the assays performed. In total, we performed 328 high
resolution molecular proﬁling studies of these samples.
We mapped the epigenomes of BCL and normal B cell samples
using chromatin immunoprecipitation and sequencing (ChIP-seq) for
H3K9/K14ac (H3ac) and H3K27ac, which mark active enhancers and
actively transcribed genic regions, H3K4me1, which marks active and
poised enhancers, and FAIRE-seq [58] to identify regions of open
chromatin, which are located within active enhancers and promoters
and indicate the binding of transcriptional regulatory factors. Whole
transcriptome gene expression was proﬁled with RNA-seq and RNA
microarray (Fig. 1). Immunoglobulin heavy and light chain clonotype
analysis [52] of RNA-seq data revealed a single dominant clone in
87% (20/23 tested) of BCL samples compared to a polyclonal pattern
in healthy control B cells, indicating substantial disease burden (Fig.
S1 and Table S1). Clonotype analysis corroborated pathology review,
which showed that all biopsies harbored >80% malignant B cells. We
identiﬁed genome-wide copy number alterations in BCL samples
using SNP microarray analysis. Integrative analysis of these ‘omics
datasets compared BCL subtypes with healthy control B-cell subsets,
mapped enhancer - gene associations, and identiﬁed a novel superenhancer for experimental studies (Fig. 1). This extensive dataset
enabled us to identify and correlate epigenetic, transcriptomic, and
genetic differences and commonalities between three different
mature B-cell neoplasms and normal B-cell subsets.
3.2. Epigenetic differences linked to gene expression changes distinguish
BCL subtypes and healthy control B cells
To identify distinct chromatin and gene expression patterns for
BCL subtypes, we developed an integrative bioinformatics pipeline to
deﬁne putative regulatory elements across the genome and correlate
changes in ChIP-seq signal or chromatin accessibility (FAIRE-seq) at
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Fig. 2. Super-enhancers are selectively gained and lost at key transcriptional regulators in B-cell cancers. A) Venn diagram shows the overlap of differentially accessible (FAIREseq) or differentially bound chromatin (H3K27ac-, H3ac-, H3K4me1- ChIPseq) (absolute log2 fold change > 2, FDR < 0.01) in WUSM BCL compared to healthy control CD19+ B-cells sorted from tonsils. B) Heatmaps show the log2 ratio of signal for H3K27ac-, H3ac-, H3K4me1-, and FAIRE-seq at differentially bound (as in A) H3K27ac peaks between all BCL subtypes and hc B-cells. C) Venn diagram
shows the shared and unique super-enhancer (SE) calls in BCL subtypes and healthy control (HC) B-cells. D) Bar graphs show RNA-seq log2 fold changes of genes near enhancers and SE with
increased H3K27ac signal (log2 fold change > 1, FDR < 0.01) between BCL subtypes and healthy control B-cells compared to genes near enhancers and SE that are not increased, grouped by
BCL subtype. E) The same as (D), but for genes near enhancers and SE with decreased H3K27ac signal (log2 fold change < 2, FDR < 0.01). Mann Whitney test, ns not signiﬁcant, * P < 0.05, ** P
< 0.01, *** P < 0.001, **** P < 0.0001. Mean with 95% conﬁdence intervals shown. F-K) SE-associated genes with signiﬁcantly increased (F-H) or decreased (I-K) expression and differentially
bound SEs in BCL subtypes. Normalized RNA-seq TCF4 (F) or DNMT1 (I) gene counts grouped by BCL subtype and HC B-cells (DESeq2, ** adj p < 0.01, **** adj p < 0.0001, ***** adj p < 1e-5). Normalized RNA microarray signal for TCF4 (G) or DNMT1 (J) grouped by BCL subtype and healthy control germinal center (GC) centroblasts (CB), centrocytes (CC), naive and memory B-cells
(limma * adj p < 0.05, ** adj p < 0.01, *** adj p < 0.001). Scatter plot shows signiﬁcant correlation of TCF4 (H) or DNMT1 (K) expression (RNAseq) with H3K27ac levels at the associated SE
(Spearman correlation).
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these elements with expression of nearby genes (Fig. 1). We used
MACS2 [59] to call peaks (q-value < 0.05) in all ChIP and FAIRE-seq
datasets. Overlapping peaks called in at least three samples for each
histone mark (ChIP-seq) or FAIRE-seq were merged. All ChIP-seq and
FAIRE-seq datasets were then merged to derive a consensus peak set
(Table S2). We used ChIPseeker [60] to annotate this consensus discovery set based on genomic location, segregating exon-overlapping
peaks from putative regulatory elements (promoter, intronic, or
intergenic peaks). Putative promoter and enhancer elements
(intronic or intergenic peaks) were compared to the GeneHancer [61]
database, a set of conserved regulatory elements generated from dozens of cell lines/tissues, including B-cell lines.
Our comparisons demonstrated that 76.8% of the putative B-cell
enhancers and promoters (57,771/75,204) overlapped one or more
GeneHancer regulatory elements (Fig. S2A). The remaining 17,433
comprise putative regulatory elements that are unique to primary
mature B cells or to mature B-cell cancers, as these cell types are not
represented in the GeneHancer database. We next compared the epigenetic landscapes in all BCL samples to healthy control CD19+ B cells
to deﬁne differentially bound/accessible (DB) regulatory elements
(FDR < 0.01; log2 fold-change > 2) using the DiffBind R package [62]
for each histone mark (ChIP-seq) and for FAIRE-seq (Table S2). We
evaluated the co-occurrence of DB peaks to identify unique and overlapping regions for these discrete gene regulatory modiﬁcations. As
shown in Fig. 2A, H3K4me1 positive regions have the greatest proportional overlap with other histone marks and open chromatin
(67%), as expected for this marker of both poised and active
enhancers. Differentially accessible peaks (FAIREseq) had the greatest
proportion of unique peaks, likely due to the fact that open or closed
chromatin in these regions is often associated with reduced nucleosome density for the former and repressive chromatin for the latter,
either of which would reduce the amount of H3K27ac, H3K9/14ac,
and H3K4me1 in these regions [31]. The coincidence of active marks
H3K27ac and H3K9/14ac in differentially bound peaks (1290) was
high, as was the coincidence of H3K27ac, H3K9/14ac, and H3K4me1
(691), indicative of differentially active enhancers in BCL.
To identify epigenetic regulatory elements with altered activity that
is distinct or shared to each BCL subtype, we performed pairwise comparisons of each B-cell cancer type with healthy control B cells to deﬁne
DB elements as before (FDR < 0.01; absolute log2 fold-change > 1). We
focused on H3K27ac as the baseline set because this modiﬁcation marks
active enhancers and because we had H3K27ac ChIPseq data for the
greatest number of BCL and healthy control B-cell subsets (Fig. S1). To
ensure that the DB elements are cancer related, and not due to comparison with an inappropriate normal B-cell subset, we compared the chromatin proﬁles of each of the normal B-cell subsets: centrocytes [5],
centroblasts [5], naïve [3], memory [3], and total CD19+ B cells [20] puriﬁed from tonsils. We found that 97% or greater of their proﬁle peaks
overlap, except for memory B cells (75%), and importantly, only 0.27% of
the non-overlapping peaks (38/14168) were differentially bound/accessible compared to BCL samples. Thus, we concluded that, for identiﬁcation of DB elements in BCL, the chromatin proﬁles of the healthy control
CD19+ B cells effectively represent the epigenetic landscapes of the other
B-cell subsets. Overall, chromatin accessibility and all other histone modiﬁcation proﬁles exhibit similar signal patterns at H3K27ac DB elements
in each of the BCL subtypes and are highly correlative (Pearson correlation r = 0.843-0.949, n = 7,772, Fig. S2B). Notably, DB elements for all histone modiﬁcations and chromatin accessibility occur more frequently
than expected at enhancers (Chi-square test; ****, P < 0.0001; Fig. S2C).
CLL, FL and DLBCL subtypes exhibit distinct patterns of chromatin
accessibility and histone modiﬁcation compared to each other and to
healthy control B-cell subsets. Log2 ratio heatmaps of histone marks
and chromatin accessibility show eight distinct clusters of regulatory
elements with similar patterns of epigenetic activity (Fig. 2B). The
largest single cluster (1, n=1903) contains elements with decreased
levels of all histone marks and decreased chromatin accessibility for
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all BCL subtypes. Cluster 2 is the next largest (n=1198) and contains
elements with increased levels of chromatin modiﬁcation and accessibility across BCL subtypes. Clusters 3 5 include elements increased
in one or two subtypes, while elements in clusters 6 8 are decreased
in one or two subtypes.

3.3. Key BCL driver genes are marked by super-enhancers
Super-enhancers (SE) are clusters of enhancers that control the
expression of key cell identity and developmental genes [38] and
arise during pathogenic events to drive oncogene expression
[37,47,63,64]. We and others have shown that SEs contribute to Bcell cancers [18,44,47,65], which led us to further investigate SE
dynamics in this dataset. We used the ROSE [37] tool to identify SEs
from H3K27ac data for each BCL and HC B cell sample and derived a
consensus set (n = 1367) by merging those that overlapped; nearly all
(1254/1367, 91.7%) overlapped a previously described SE by at least
25% (dbSUPER [66] database). The majority of SEs were detected in
multiple BCL subtypes and HC B cells; a minority (23.6%, 322/1367)
were identiﬁed in only one. BCL subtypes were more similar to each
other than to HC B cells, which harbored 210 SEs that were not
detected in any BCL sample (Fig. 2C). Comparison of BCL to healthy
control B cells revealed that 28.9% (395/1367) of SEs had signiﬁcantly
different levels of H3K27ac (absolute log2 fold change > 1; FDR <
0.01, DiffBind [62]; Table S3). To evaluate the effect of enhancer chromatin changes on gene expression, we divided total enhancers into
DB increased or decreased SE and typical enhancer groups. We calculated the log2 fold change in gene expression (RNA-seq) for each BCL
subtype relative to healthy control B cells and identiﬁed the gene
most proximal to each DB element. As expected, genes near DB elements with increased histone acetylation in BCL groups exhibited a
corresponding signiﬁcant increase in expression fold change, with
greater than two-fold (linear) increases in all comparisons. Increased
SEs and typical enhancers had similar impacts on gene expression
(Fig. 2D). However, we were surprised to ﬁnd that decreased acetylation of SEs in BCL compared to healthy control B cells was associated
with a much larger change in expression - up to 5-fold (linear)
decrease (Fig. 2E). Taken together, these results demonstrate that BCL
subtypes have distinct epigenetic changes compared to each other
and to healthy control B cells, and that these differences correlate
with expression changes in nearby genes. Most striking was that loss
of SE acetylation had a greater impact on gene expression than
increased acetylation. These ﬁndings suggest that loss of activity at
key SEs may be an important contributor to BCL pathogenesis.
We next asked whether these DB SEs are associated with B-cell
lymphoma oncogenes or tumor suppressor genes. Increased expression of TCF4 (E2-2), a basic helix-loop-helix transcription factor a critical for germinal center B and plasma cell development [67,68], has
been reported in FL and DLBCL and likely contributes to lymphoma
pathogenesis [69,70]. Here we found that TCF4 expression is signiﬁcantly elevated (2.5- to 6-fold) in all BCL subtypes compared to all
healthy control B-cell subsets (germinal center centrocytes and centroblasts, naïve and memory B cells) (Fig. 2F-G). Levels of K27ac
within the TCF4 SEs are signiﬁcantly correlated with expression level
(r=0.6642, p<0.0005) (Fig. 2H). DNMT1 is a maintenance DNA methyltransferase whose downregulation has been implicated in EBV
latency and is associated with worse outcomes in DLBCL [71 73]. We
detected signiﬁcantly lower (2- to 10-fold) DNMT1 expression in all
BCL subtypes compared to all healthy control B-cell subsets (Fig. 2I-J).
In addition, levels of H3K27ac within the DNMT1 SE signiﬁcantly correlate with expression across all samples (r=0.8480, p<0.0001)
(Fig. 2K). Together, these studies demonstrate that altered SE activity
is recurrent across FL/DLBCL and CLL and these changes correlate
with expression changes in neighboring genes with likely roles in
lymphoma pathogenesis.
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Fig. 3. A novel super-enhancer associated with dysregulated high expression of PIGR and FCMR mRNA and protein. A) Genome browser screenshot shows signal for histone modiﬁcations (ChIPseq) and chromatin accessibility (FAIREseq - WUSM samples; DNase-seq - small intestine sample from Roadmap Epigenomic Project) for the FCMR/PIGR locus. Regulatory elements that were tested in luciferase assays are highlighted in gray. GeneHancer regulatory elements (red - promoter; gray - enhancer; darker color indicates higher
conﬁdence) and the identiﬁed super-enhancer are also shown. All tracks are RPKM normalized. Regions of copy number alteration (CNA) are shown by a red bar (ampliﬁcations
identiﬁed in FL samples). B) Luciferase reporter assay results for all regulatory elements shown in (A). Assays were read in triplicate and performed at least twice. Mean with standard deviation shown. C-F) Expression of FCMR (C-D) and PIGR (E-F) determined by RNAseq (C&E) and RNA microarray (D&F) for BCL subtypes and healthy control B cells and B cell
subsets (germinal center (GC) centroblasts (CB), centrocytes (CC), naive and memory B cells). RNAseq analyzed by DESeq2; microarrays analyzed by limma. * adj p > 0.05, ** adj p <
0.01, *** adj p < 0.001, **** adj p < 0.0001, ns not signiﬁcant. G) Immunoﬂuorescence microscopy for PIGR in puriﬁed primary CLL B-cells, MEC1 (CLL cell line), LS180 (colorectal cancer cell line), and HH (T-cell lymphoma cell line).
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3.4. BCLs harbor a novel SE for immunoglobulin receptor genes FCMR
and PIGR
We next used our unique approach for comparing gene regulation
across multiple BCL subtypes to search for a novel BCL SE, reasoning
that such an element may represent a shared oncogenic pathway in
these disparate B-cell neoplasms. We identiﬁed an SE overlapping
the immunoglobulin (Ig) receptor genes FCMR and PIGR that harbored several constituent elements with high levels of active and
open chromatin (FAIRE/H3K27ac ChIP-seq) across all three BCL subtypes compared with healthy control B cells (Fig. 3A). A subset of
BCLs harbored genome copy number gains in this region (2 FL, 2
DLBCL). In comparison, PIGR is normally expressed in intestinal
mucosal epithelium and as expected, the PIGR gene body and ﬂanking
regions harbored active chromatin in small intestine (DNase/
H3K27ac ChIP-seq, Roadmap Epigenomics Project17).
Because FCMR and PIGR expression is mutually exclusive in immune
and mucosal epithelial cells, respectively, we reasoned that elements
within the FCMR/PIGR SE may differentially regulate these genes in each
cell type. We identiﬁed 6 putative component elements and 5 ﬂanking
potential regulatory elements based on overlapping accessible chromatin, H3K27ac, H3ac, and H3K4me1 in BCLs, healthy control B cells, and
small intestine (Fig. 3A). To directly compare these elements in B cells
and epithelial cells, we performed luciferase reporter assays in a B-cell
line (Raji) and a colorectal cell line (LS180). Fig. 3B shows that four elements have robust enhancer activity in at least one cell type (REs 6, 7, 8,
and 10). An element located within the super enhancer at the 3’ end of
PIGR (RE6) has the greatest enhancer activity in both cell types, with 10or 17-fold higher relative luminescence compared to the empty vector
in B or colorectal cells, respectively. The relative luciferase activity
induced by these elements in B cells versus colorectal cells did not
always correlate with the relative levels of active or open chromatin
detected FAIRE/DNase/ChIP-seq (e.g., RE6 versus RE7), suggesting that
other factors that are absent from luciferase reporter plasmids, such as
chromatin modiﬁcations and 3D genome organization [74], may be
responsible for the tissue-speciﬁc expression of FCMR and PIGR. Indeed,
there are several CTCF peaks ﬂanking the FCMR promoter and the dense
cluster of enhancers (RE2 - RE6) (Fig. S3A). CTCF is a DNA binding protein that forms chromatin loops that facilitate or inhibit promoterenhancer or promoter-silencer interactions19. Moreover, high resolution
Hi-C data from GM12878 B cells shows at least 6 chromatin interaction
contact points in the region between RE1 in FCMR and RE6 in PIGR (Fig.
S3A) [75,76]. Together, these data suggest that the strong enhancer cluster between FCMR and PIGR is tethered closely to the FCMR promoter in
B cells. Overall, these results demonstrate that several enhancers
throughout the FCMR/PIGR locus have robust regulatory activity in both
cell types and suggest that 3D genome organization and chromatin
modiﬁcations are likely responsible for the tissue-speciﬁc expression of
FCMR and PIGR in non-malignant B cells.
In support of a functional role for this SE, the expression levels of
FCMR were strikingly upregulated in CLL, and PIGR expression was
signiﬁcantly elevated in both CLL and DLBCL compared to healthy
control B-cell subsets (Fig. 3C-F). FCMR is a high-afﬁnity IgM receptor
expressed by T and B lymphocytes, as well as NK cells. PIGR is a highafﬁnity IgA/lower-afﬁnity IgM receptor normally expressed only in
mucosal epithelial cells, where it transports Ig proteins produced by
B cells from the basolateral surface across the cell to be secreted at
the apical surface into the lumen of the gut or respiratory tract. FCMR
overexpression in CLL has been previously reported [77,78], though
its role in CLL pathogenicity remains unresolved. To our knowledge,
PIGR expression has not been reported previously in normal or malignant human B cells, though it was expressed in a murine B-cell lymphoma line [79].
We validated and extended these ﬁndings in two additional
cohorts. A recent study comparing RNA-seq of CLL to naive and memory B cells [22] shows similar upregulation of FCMR and PIGR as seen
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in our study (Fig. S3B-C). We also compared our dataset to a cohort
that includes CLL, DLBCL, and FL, as well as mantle cell (MCL),
mucosa-associated (MALT), and nodal marginal zone (NMZL) lymphomas [80]. Consistent with our study, FCMR expression is signiﬁcantly increased in CLL and MCL relative to whole tonsil and lymph
node samples (Fig. S3D). The expression in DLBCL samples is relatively lower, but this may be due to the ratio of GCB to ABC/non-GCB
samples, which is not reported [80]. Our dataset contains an equal
number of each DLBCL subtype and shows a trend toward a higher
level of FCMR expression in ABC/non-GCB DLBCL samples (median
ABC = 10.91, median GCB = 9.81, P = n.s.). Also consistent with our
data, PIGR expression is signiﬁcantly higher in CLL and DLBCL, as well
as in MCL and MALT lymphomas (Fig. S3E). Together, these results
demonstrate that elevated expression of FCMR and PIGR is shared
across diverse mature B-cell malignancies and suggest a potential
role for one or both proteins in BCL pathogenesis.
Having demonstrated signiﬁcantly elevated FCMR and PIGR mRNA
in BCL, we sought to validate this ﬁnding at the protein level. Using
ﬂow cytometry, we show high levels of FCMR surface expression in
CD19+ B cells from three primary CLL samples (Fig. S3F), which is consistent with previous reports [77,78]. To evaluate PIGR, we performed
immunoﬂuorescence followed by confocal microscopy and demonstrated high levels of PIGR in CD19+ primary CLL cells and a CLL cell
line (MEC1). As expected, PIGR expression was also high in a colorectal (mucosal epithelial) cell line (LS180), whereas expression was
substantially lower in a T cell lymphoma line (HH) (Fig. 3G).
Taken together, these data demonstrate the complex interplay
of epigenetic modiﬁcation, genome conformation, and transcriptional regulators in the tissue-speciﬁc regulation of FCMR and
PIGR. All of these control mechanisms are known to be disrupted
in lymphoma [3,81] and may contribute to the deregulated
expression observed in BCL.
3.5. A subset of genome copy number alterations (CNA) exhibit
corresponding epigenetic changes
Alterations in genome copy number are a major driver of oncogenesis, including the ampliﬁcation of oncogenes and deletion of
tumor suppressor genes. We reasoned that gain or loss of genome
regulatory regions could similarly impact the expression of key lymphoma pathogenesis genes. To identify copy number alterations, we
compared puriﬁed B cells from DLBCL, FL, and CLL samples to healthy
control B cells or a composite healthy control reference human
genome using SNP microarrays. Using a log2 copy number fold
change cutoff of +/ 0.2, we identiﬁed a range of 135 to 4907 (median
1443.5) regions of copy number alteration (CNA) in BCL samples
(Table S4). We next evaluated the overlap of CNA with enhancers
(Fig. 2) and found that 17.12% of enhancers overlap ampliﬁcations,
5.13% overlap deletions, 0.07% overlap deletions and ampliﬁcations
in different samples, and the majority of enhancers, 77.67%, do not
overlap a CNA (Fig. 4A). Percent overlaps were similar for CNAs with
SEs (Fig. S4A). To determine if regulatory elements with CNA have
altered chromatin activity that is consistent with the CNA type, we
compared the log2 fold change of BCL versus healthy control B cells
for elements overlapping ampliﬁcations, deletions, or no CNA, requiring that the CNA be detected in at least 10% of BCL samples. For each
chromatin mark (H3K27ac, K3K4me1, K3K9ac) and open chromatin
(FAIRE), those overlapping ampliﬁcations had signiﬁcantly higher
mean levels of activity and those overlapping deletions had signiﬁcantly lower mean levels of activity compared to those without CNA
overlap (Fig. 4B), with the exception of H3K27ac in elements overlapping deletions. The lack of signiﬁcant difference could be due to the
relatively lower number of DB elements overlapping deletions
(Fig. 4C).
Genome copy number alterations are sometimes associated with a
corresponding change in the expression of genes within the altered
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Fig. 4. A subset of genome copy number alterations in BCL have corresponding epigenetic and expression changes. A) Pie chart shows the percentage of enhancers containing genome copy
number alterations (CNA) in at least 10% of BCL samples. Amp - ampliﬁcation, Del - deletion, Amp&Del - ampliﬁcation or deletion detected in the same region in different samples. B) Mean +/
standard deviation (SD) of log2 fold change of BCL versus healthy control (HC) B cells for open chromatin (FAIREseq) and epigenetic marks (H3K27ac, H3ac, H3K4me1 ChIPseq) in enhancers containing CNA or not. Letters above SD lines indicate statistical comparator group (A - ampliﬁcation, D - deletion, N - No CNA); superscript indicates adjusted p value (* p < 1e 04, ** p < 1e 5, ***
p < 2e 16, ns not signiﬁcant; one-way ANOVA with Tukey HSD). C) Plot shows the K27ac log2 fold change of BCL versus HC B cells of differentially bound (DB) enhancers with overlapping
Amp, Del, or no CNA. Statistics as in (B). D) Volcano plot shows log2 fold change and -log10 adjusted p value for expression (RNAseq) in DLBCL versus HC B cells. Differentially expressed genes
(absolute log2 fold change >1 and adjusted p < 0.01) are pink. Genes with differential expression and CNA are highlighted by text color and triangle shape and color: red/point
up = ampliﬁcation, blue/point down = deletion. Not differentially expressed and no CNA = grey. E) Volcano plot as in (D) for FL versus healthy control B-cells. F) Whole genome plot of number
of BCL samples with copy number ampliﬁcation (red) or deletion (blue) in 100kb bins. Differentially expressed genes (from D or E) with CNA in > 10% of BCL samples are labeled on the upper
panel if they overlap an ampliﬁed region and on the lower panel for deleted regions. Gene label color indicates if expression is increased (red) or decreased (blue) in BCL relative to HC B cells.
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region [82]. We evaluated this for genes within CNA present in at
least 10% of samples, separated by BCL subtype. Using cutoffs for signiﬁcantly different gene expression (adjust p < 0.01, absolute log2
fold-change >1, DEseq2), we determined that expression fold change
corresponds to CNA direction (FC increase - ampliﬁcation; FC
decrease
deletion) for 50% to 61.5% of differentially expressed
genes for each BCL subtype and CNA type. Simple cutoffs do not convey the magnitude of fold change expression difference, however. To
evaluate this, we generated volcano plots and highlighted genes in
CNAs with triangles with point direction and color indicating gain
(up, red) or loss (down, blue). As shown in Figs. 4D-E and S4B genes
overlapping genome ampliﬁcations had increased fold change and
those with deletions had decreased fold change, though many genes
with non-corresponding gene expression and CNA were also seen.
Several genes with known roles in B-cell lymphoma demonstrate
corresponding expression and copy number changes in the volcano
plots, including BCL2, TNFRSF14, A2M, TCF4, and TP53. Multiple other
transcriptional regulators, epigenetic factors, and DNA repair factors
also show corresponding changes, such as KDM5A, KDM5B, SETBP1,
NSD1, TRAF3IP2, TP73, WRAP53, and several histone genes. Many of
these genes are in large regions of CNA, such as whole chromosome
ampliﬁcation (chr 12, chr 18) or deletion (chr 6), but some are in relatively small regions, such as NSD1 in chromosome 5 and TCF7L2 in
chromosome 10 (Fig. 4F). These data demonstrate that genome copy
number change is likely responsible for some amount of transcriptional dysregulation in B-cell lymphoma, but that other mechanisms
play a substantial role in the altered expression of most genes.

3.6. Dysregulated transcription factors exhibit corresponding epigenetic
changes in differentially bound enhancers
Transcriptional regulation is a carefully choreographed dance
involving genome regulatory elements, chromatin landscapes, and a
diverse set of protein modulators. Key among the last are certain
transcription factors that are known to be oncogenic in hematopoietic cells [7,83]. With this in mind, we performed a comprehensive
analysis of differentially expressed (DE) transcription factors (TF) to
identify perturbed regulatory circuits that may contribute to lymphoma pathogenesis. Limiting our analysis to 1639 expertly curated TFs
[84], we found 283 were differentially expressed (adjusted p-value <
0.01; absolute log2 fold change > 2) in at least one BCL subtype compared to healthy control B-cell subsets (DE TFs). Hierarchical clustering of
RNA-seq data for these DE TFs deﬁned 6 clusters of distinct expression
proﬁles that separate BCL subtypes and healthy control B cells, with
some overlap of FL and DLBCL samples. The two DLBCL groups did not
separate GCB and non-GCB subtypes, which were conﬁrmed by pathology review and by RNAseq (BCL6, IRF4/MUM1, CD10, LMO2), but rather
had an equal number of non-GCB in each group (2 non-GCB, 3 GCB), suggesting that the differences in TF expression proﬁles transcend the GC/
ABC designations (Fig. 5A and Table S5). The 176 DE TFs in Clusters 1-3
were more highly expressed in all BCL subtypes compared to healthy
control B cells, with CLL and DLBCL groups exhibiting higher expression
in Clusters 1 and 2, respectively. In contrast, the expression of 107 DE TF
genes in Clusters 4 6 was signiﬁcantly lower in one or more BCL subtypes compared to healthy control B cells, with Cluster 4 TFs more downregulated in FL and Cluster 5 more downregulated in CLL. Cluster 6 TFs
were uniformly downregulated across BCL subtypes. This unbiased transcriptome analysis revealed genes that were also identiﬁed by epigenetic
and CNA analyses above, such as SETBP1, TCF4, and TP53 (Figs. 2F-H, 4DF). To evaluate the contribution of CNA and epigenetic regulation to the
signiﬁcant transcriptional changes observed in these DE TFs, we compared the number of TF genes in CNA with the number that overlap with
differentially bound enhancers (adjusted p-value < 0.01; absolute log2
fold change > 1). Fig. 5B shows that, for each cluster, a greater number of
TFs overlap differentially bound enhancers than overlap CNA.
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There are many more enhancer elements throughout the genome
than there are genes, and single genes are often controlled by multiple enhancers [85]. We reasoned that the large changes in expression
of these DE TFs may be due to the transcriptional regulatory impact
of multiple DB enhancers. The volcano plot in Fig. 5C demonstrates
that many of the TFs overlap with up to 20 or more DB enhancers
that largely correspond with the gene’s expression change. Of those
with increased expression and DB enhancers, 33 had increased
enhancers, 12 had decreased, and 3 had both increased and
decreased - though more increased than decreased. Of those with
decreased expression and DB enhancers, 28 had decreased enhancers
and 12 had increased. Because this analysis required overlap of
enhancers with the TF genes, the largest genes had the greatest number of overlapping and DB enhancers, though some smaller genes
also had similar numbers (Fig. 5D).
Pathway enrichment analyses revealed that Clusters 1-3, which
exhibit signiﬁcantly higher expression in BCL, are enriched in TFs
involved in transcriptional regulation, WNT and beta-catenin signaling, and pathways downstream of key TFs such as TCF/LEF and RUNX
families, suggesting that altered expression of multiple TFs within
shared pathways reinforces aberrant regulation of pathway target
genes. Clusters 4-6, with signiﬁcantly lower expression in BCL, are
enriched in TFs associated with cellular senescence and TP53-dependent apoptosis pathways. Cluster 6 in particular contains many
known tumor suppressors and TFs crucial for B-cell development and
differentiation, including TP53 [7,21], EGR1/2/3/4 [86], RUNX3 [87],
and SPI1(PU.1) [88,89], among others (Fig. S5 and Table S6).
3.7. Lymphoma oncogenes and tumor-suppressors have self-targeting
transcriptional feedback programs
Having determined that many BCL-dysregulated TFs have multiple DB conventional enhancers overlapping the genes, we reasoned
that SEs may also control their transcription. We allowed a distance
of up to 250kb from genes to SEs, since SEs are often located many
kilobases or even megabases away from their gene targets [37,38,47].
We identiﬁed 152 SEs located within 250kb of the 283 TFs in Clusters
1-6. Of these, 59 SE were associated with Cluster 1-3 TFs, which are
highly expressed in BCL, and 86 SEs were associated with Cluster 4-6
TFs, which are signiﬁcantly downregulated in BCL. Notably, there
were fewer SEs associated with Cluster 1-3 TFs, even though there
are a greater number of TFs in Clusters 1-3: 59 SEs and 40/176 Cluster
1-3 TFs vs 86 SEs and 54/107 Cluster 4-6 TFs). We next performed a
similar analysis with SEs as we did with DB enhancers (Fig. 5). Compared to enhancers (Fig. 5D), the number of SEs was less concordant
with gene size, likely due to the much larger size of SEs and the ﬂanking distance allowed (Fig. S6A). However, the expression of DE TFs
was generally concordant with the number and fold change direction
(up/down) of DB SEs within 250kb of the TF gene’s boundaries (Fig.
S6B). Overall, SEs within 250kb of BCL-upregulated TFs in Clusters 13 harbored signiﬁcantly higher levels of H3K27ac in BCL compared to
healthy control B cells, while those associated with BCL-downregulated TFs in Clusters 4-6 exhibit signiﬁcantly lower H3K27ac levels in
BCL subtypes. The difference was even more striking for SEs that
overlap DE TF genes (Fig. 6A).
In addition to controlling transcription at promoters, TFs also
function more broadly as epigenetic regulators by opening or maintaining open chromatin and by recruiting chromatin regulators and
other transcription factors at promoters and enhancers [37,90,91].
We therefore reasoned that the DE TFs may act in this way on their
neighboring SEs, with the upregulated TFs in Clusters 1-3 acting to
increase active SE chromatin and the decreased levels of TFs in Clusters 4-6 resulting in decreased active SE chromatin (cartoon in
Fig. 6B). This proposed mechanism of epigenetic regulation does not
take into account the potential effects of transcriptional repressors or
co-regulation with other factors but does evaluate a major
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Fig. 5. BCL-altered transcription factor expression proﬁles associated with genome copy number alterations and differentially bound enhancers. A) Heatmap shows normalized gene count zscores (RNA-seq) for transcription factors (TF) differentially expressed (adjusted p-value < 0.01, absolute log2 fold change > 1, n = 283) in at least one BCL subtype compared to healthy control
(HC) B-cells. Six clusters of distinct expression proﬁles were detected; the number of genes is shown beneath each cluster label. B) Bar chart show the number of TFs with copy number alterations and differentially bound (DB) enhancers in each cluster. (Left) Copy number (CN) ampliﬁed, DB increased H3K27ac in BCL (DB up); (Right) CN deletion, DB decreased H3K27ac in BCL (DB
down). C) Volcano plot shows log2 fold change and -log10 adjusted p value for expression of TFs (as in A) in BCL versus HC B cells. TF genes with overlapping DB enhancers are highlighted by
color (red = increased, blue = decreased, grey = unchanged level of histone acetylation) and size (corresponding to the number of DB enhancers). Color of the gene label corresponds to the status
of the overlapping DB enhancers (red = all increased, blue = all decreased, purple = both increased and decreased DB enhancers overlap). D) XY plot shows the number of total enhancers overlapping each TF (Y axis) by TF gene size in kilobases (kb) (X axis). Size and colors as in (C). E) Whole genome frequency plot of number of BCL samples with copy number ampliﬁcation (red) or
deletion (blue) (100kb bins). TFs (from A) with at least 3 samples with overlapping CN alterations (CNA) are labeled on the upper panel if they overlap an ampliﬁed region and on the lower
panel for deleted regions. Gene label color indicates if expression is increased (red) or decreased (blue) in BCL relative to HC B cells.
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Fig. 6. BCL-altered transcription factors have super-enhancer powered transcriptional feedback loops. A) Half box/dot-plot shows the log2 fold change of K27ac in BCL versus healthy control
(HC) B cells for super-enhancers (SE) within 250kb (left) or overlapping (right) the differentially expressed TF genes (red: clusters 1-3, upregulated in BCL, blue: clusters 4-6, downregulated in
BCL, from Fig. 5). Wilcoxon test *** p < 0.001; **** p < 0.0001. B) Cartoon depicts distal and overlapping SEs with high (purple) or low (grey) levels of H3K27ac regulating the expression of a TF
gene from one of clusters 1-3 (red) or 4-6 (blue). TFs from the same (matching) cluster groups (1-3/4-6) bind within the SEs and control TF expression. C) Volcano plot shows log2 fold change
and -log10 adjusted p value for expression of TFs (from Fig. 5) in BCL versus HC B cells. TF genes with SE within 250kb are highlighted by diamonds, with size indicating number of SEs and color
corresponding to the percentage of matching TF cluster group peaks within the SE(s), red = TF gene in Clusters 1-3, blue = TF gene in Clusters 4-6 (ENCODE 3 TF ChIPseq). Gene labels include the
number of SEs if greater than one. D) Alluvial plot segregates TFs with overlapping SEs and ENCODE 3 ChIPseq data. “Self” TF peaks: ChIPseq binding peaks for a TF were found in the SE overlapping the gene encoding that TF, an indication of TF self-regulation. E) For 15 TFs with “self” TF peaks in overlapping super-enhancers from (D), bar graphs show the number of constituent
enhancers with (red/blue) or without (grey) binding peaks of the “self” TF. Red = TF in Clusters 1-3, blue = TF in Clusters 4-6.
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mechanism of epigenetic regulation: that of activation. To test this
hypothesis, we retrieved TF ChIP-seq peaks in SEs within 250kb of
BCL-altered TFs from the ENCODE studies [31]. Factorbook [92] contains ChIP-seq data from 682 TFs from 142 human cell types; peaks
from 665 of these TFs were found across all SEs in our dataset. Of 283
BCL-altered TFs, 89 had ChIP-seq data available in Factorbook. To
evaluate the relative regulatory impact of TF cluster groups, we
determined the number of TF peaks from Clusters 1-3 and 4-6 in
each SE within 250kb of BCL-altered TFs, the total of which varied
from 4 to 1500. Given this wide range, we expressed the relative regulatory impact of TF cluster groups as a percentage of the total TF
peaks in any cluster. For simplicity, the percentage of “matching” TF
cluster groups peaks is plotted in Fig. 6C (e.g., ChIP-seq peaks for a TF
in Cluster 1-3 in an SE associated with a TF gene in Cluster 1-3). For
SEs within 250kb of upregulated TFs (Clusters 1-3), a red color gradient (0 100%) indicates the percentage of TF peaks that are from Clusters 1-3 or “matching”; for Clusters 4-6, the color gradient for
matching TF peaks is blue. We found that SEs within 250kb of Cluster
4-6 TFs have a majority of matching Cluster 4-6 TF peaks. In fact, 51/
54 TFs had greater than 50% matching (Cluster 4-6) TF peaks in all
SEs (median 60.2% for all SEs). In contrast, only 6/40 Cluster 1-3 TFs
had greater than 50% matching (Cluster 1-3) TF peaks in all SEs
(median 41.2% for all SEs). In addition, a greater number of Cluster 46 TFs have multiple SEs within 250kb of their gene (28/54 vs 13/40,
size of diamond, Fig. 6C).
Having identiﬁed a correspondence of expression changes and TF
peaks in SEs associated with DE TFs groups, we next focused our analysis on the potential role of TF self-regulation. To accomplish this
more stringent analysis, we required that SEs overlap DE TF genes.
Just as for SEs within 250kb, there were fewer Cluster 1-3 TFs with
overlapping SEs [13] than cluster 4-6 TF [25] as shown in the alluvial
plot in Fig. 6D. Of these, 18 TFs had ChIP-seq available from ENCODE
(5 in Clusters 1-3, 13 in Clusters 4-6). We next evaluated the number
of “self” TF ChIP-seq peaks within each SE, i.e., TF binding by the protein encoded by the SE-overlapping gene. All but three of the TFs had
binding within their overlapping SEs (15/18). To quantify the relative
regulatory impact of these “self” TF peaks we determined the number
of constituent enhancers with self TF peaks within each SE. Fig. 6E
demonstrates that these SEs harbor self TF peaks in a variable number
of constituent enhancers, from 1
7 (4 100% of total constituent
enhancers). TFs in Clusters 4-6 harbored self TF peaks in a higher percentage of constituent enhancers: median 33.3% vs 12.5% in Cluster
1-3 TF SEs. Together, these data suggest that BCL DE TFs act to promote and/or maintain epigenetic changes in their super-enhancers,
forming self-regulating transcriptional feedback loops that may promote lymphoma pathogenesis.
4. Discussion
Disordered epigenetic landscapes and transcriptional regulation
are known contributors to the pathogenesis of germinal center B-cell
lymphomas (FL, DLBCL) and to chronic lymphocytic leukemia. However, the regulomes of these mature B-cell malignancies had not
been previously evaluated together to identify shared and distinct
pathways of oncogenesis. In this study, we proﬁled the chromatin
landscapes of these three B-cell cancers, as well as their normal B-cell
counterparts. We identiﬁed recurrent regulatory programs across
BCL subtypes and a novel super enhancer locus driving tissue-speciﬁc
expression of two immunoglobulin (Ig) receptor genes with aberrant
expression in BCL. Most strikingly, we showed that BCL is marked by
profound reductions in normal B-cell transcription factor expression,
and that this may be mediated and reinforced by loss of self-regulatory feedback loops to the TF-associated SEs.
By comparing the regulomes of FL, DLBCL, and CLL, we identiﬁed a
novel SE in each of the three subtypes that we linked to overexpression of its ﬂanking genes. The SE locus is intriguing from both cancer

and normal development perspectives. The ﬂanking Ig receptor
genes, FCMR and PIGR, are expressed in a mutually exclusive pattern
in B lymphocytes and mucosal epithelial cells, respectively, but corresponding regulatory mechanisms had not previously been elucidated.
Our studies suggest that expression is controlled by differential patterns of histone marks and chromatin accessibility as well as chromatin interactions via CTCF. Based on our studies, multiple CTCFmediated chromatin interactions bring together a strong, active
enhancer and the promoter of FCMR in B cells, while lack of CTCF and
active chromatin marks “loop out” this enhancer away from the promoter in mucosal epithelial cells. Meanwhile, high levels of active
chromatin marks in the ﬂanking region overlapping PIGR likely drives
expression of this gene in mucosal epithelial cells and not in B cells.
The inappropriate expression of PIGR in some BCL samples is likely
due to high levels of active histone marks and associated TFs binding
to constituent SE elements overlapping the PIGR gene body promoting transcriptional activity. Gene activation via spreading of active
histone marks, such as acetylation, is a known mechanism of
enhancer driven transcriptional control that occurs during cellular
development [93,94]. Studies in mice showed that FCMR regulates
the surface expression of the B-cell receptor (BCR) and that B cells
deﬁcient in FCMR have enhanced tonic BCR signaling and increased
differentiation [95]. Other reports connect FCMR to IgM binding and
B-cell activation in human B cells and CLL [96]. Deregulated BCR signaling is known to play a role in the survival and growth of DLBCL
and CLL [97,98]. To our knowledge, there is no previous report of
PIGR expression in human B-cell neoplasms. We suggest that FCMR
and PIGR overexpression may contribute to the aberrant BCR signaling that drives many B-cell cancers.
We identiﬁed SEs in all three subtypes of BCL and in healthy control B-cell subsets and compared their activity level. Strikingly, SEs
with decreased activity in BCL were linked to the greatest changes in
gene expression. Similarly, the most striking change in TF expression
across BCL subtypes was downregulation of normal B-cell factors.
These include known B lymphocyte differentiation factors and tumor
suppressors, and some factors with no previously established role in
B-cell cancer. Examples of the former group include SPI1 (PU.1),
POU2F2 (OCT2), and TCF3 (E2A). PU.1 is an Ets family TF that is essential for the proper development of B cells and other lineages, though
it has some redundancy with other factors [88,89,99]. Its loss via
knockout or hypermethylation is associated with pre-B-cell leukemia
or B-cell lymphoma, respectively [100,101]. Like PU.1, OCT2 cooperates with other essential factors to promote B-cell maturation
[102,103]. OCT2 is ampliﬁed in DLBCL and required for survival of
DLBCL cell lines [104]. In FL, recurrent mutations in the DNA binding
domain led to loss of transactivational activity [105]. Our study
revealed widespread loss of OCT2 expression associated with
decreased SE activity, and in some cases, genomic copy number loss,
suggesting that disparate mechanisms of POU2F2 disruption can be
oncogenic. E2A is a E protein family helix-loop-helix (HLH) TF that
plays a critical role in B and T lymphocyte development [106], is
mutated in Burkitt’s lymphoma, and is translocated in B-cell acute
lymphocytic leukemia [107,108]. Like POU2F2/OCT2, TCF3/E2A
expression and SE activity were signiﬁcantly reduced and genomic
deletions were detected in some samples. While MAZ is best known
as a transactivator of MYC, its loss as seen in our study may promote
BCL by loss of its repression of MYB, a master regulator of the germinal center reaction [109 111].
Genomic alterations are often considered a major driver of lymphomagenesis [7,112]. In our study, we found that a minority (<20%)
of differentially bound enhancers and SEs in BCL were coincident
with concordant copy number alterations (CNA), suggesting that epigenetic changes are independent of genome copy number. One
caveat to our study is that we did not identify single nucleotide variants in our lymphoma samples. Chromatin modiﬁer mutations are
well-documented in FL and DLBCL [7], with a much lower frequency
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of mutations in these genes in CLL [12,21]. Nevertheless, chromatin
modiﬁer mutations are absent in 30-80% of BCL tumors, varying by
subtype, yet we and others have found widespread changes to
the chromatin landscape in all BCL tumors [8,18 20,22,23]. Thus,
epigenetic deregulation is common, and perhaps ubiquitous in
BCL, and in a signiﬁcant proportion of cases, is not connected to
genomic mutations.
Our studies went a step further than simply identifying BCLaltered regulatory elements, TFs, and gene expression change; we
connected these transcriptional control mechanisms to each other.
Unexpectedly, our studies revealed that loss of core normal B-cell
regulatory circuitry may play a larger role in lymphomagenesis than
previously appreciated. First, we showed that changes in enhancer
chromatin activity correlates with neighboring gene expression, and
moreover that loss of acetylation in SEs was associated with a profound loss of expression. Further analysis demonstrated that TFs with
differential expression in BCL were marked by enhancers and SEs
with corresponding differences in acetylation levels. Some of these
TF genes harbored up to 20 or more DB enhancers and up to 5 DB SE.
Here again we observed a greater number of SEs with loss of active
chromatin associated with downregulated TFs compared to SEs with
increased active chromatin associated with upregulated TFs, even
though there are nearly twice as many upregulated TFs. Further
underscoring the role of loss of normal B cell development factors,
we found that a majority of TF peaks in SEs near downregulated TFs
(Clusters 4-6) are bound by TFs from these same groups. One caveat
of the TF peak analyses is that a greater proportion of downregulated
TFs in Clusters 4-6 had ChIP-seq data available compared to upregulated TFs in Clusters 1-3 (44/107 vs 45/176). To mitigate this and to
evaluate self-regulation of TF expression, we analyzed “self” TF peak
binding, i.e., binding of a TF within an SE overlapping the TF gene.
This more stringent analysis identiﬁed four upregulated and 11
downregulated TFs with “self” SE binding peaks. In addition, these
same SEs have signiﬁcantly decreased active chromatin. While other
studies have reported ampliﬁed signaling through core regulatory
circuitries in cancer [40], our ﬁndings here demonstrate the less recognized but perhaps more impactful role of decommissioning of Bcell identity pathways in the genesis of lymphoma.
Many of the cluster group or self-regulated TFs are known BCL
oncogenes or tumor suppressors, key B cell differentiation factors,
or all of the above. For example, EBF1 is a pioneer TF and a B-cell
lineage deﬁning factor, acting to establish chromatin changes that
enable activation of B cell-speciﬁc genes and repress genes associated with alternative cell fates. The loss of active chromatin in four
SEs that overlap the EBF1 gene, coupled with a substantial number
of EBF1 binding sites and loss of EBF1 expression in BCL, support a
role for super-enhancer powered transcriptional feedback loops in
the normal expression of such crucial B-cell TFs. RUNX3 is a tumor
suppressor that has not been previously associated with BCL yet
acts in pathways known to be lymphomagenic. Particularly relevant
to this study, RUNX3 inhibits oncogenic Wnt signaling by interacting with TCF4/beta-catenin and preventing their binding and activation of MYC and CCND1 promoters [113 115]. The TCF4 gene, which
codes for an E-box binding basic helix-loop-helix transcription factor, is located in a genomic ampliﬁcation in activated B-cell type
DLBCL, reported previously [69] and also detected in our study.
TCF4 drives expression of IgM and MYC in these lymphomas [69].
The combined loss of RUNX3 and increased expression of TCF4
observed across BCL in our study suggests a synergistic feed-forward loop that promotes unchecked growth and proliferation. Compared to healthy B-cells, BCL have disruptions in key TFs and tumor
suppressors and the epigenetic elements regulating these factors.
Together, these ﬁndings suggest a complex, iterative, and interactive process that links TF and epigenetic activities together to
repress B-cell maturation and promote proliferation, culminating in
transformation.
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In summary, we have taken an integrative approach to examine
and compare the epigenomes and transcriptomes of three mature Bcell neoplasms with normal B-cell subsets. Our novel approach
enabled us to deﬁne shared alterations in the regulomes of FL, DLBCL,
and CLL and identify widespread disruption of SE-powered transcriptional feedback loops. Together, our ﬁndings implicate SEs as important hubs of tumor suppressing transcriptional feedback loops that
maintain tumor suppression and developmental programs, and
when perturbed, can drive lymphomagenesis.
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